INOVIO Pharmaceuticals, Inc., a biotechnology company focused on DNA medicines for treating and protecting against HPV-related diseases, cancer, and infectious diseases, has announced its intention to conduct a public offering of its common stock. The offering includes shares and accompanying Series A and Series B warrants, with all securities to be sold by INOVIO. Piper Sandler & Co. will act as the sole book-running manager for the offering. The company has filed a shelf registration statement with the SEC, and the offering will proceed based on market conditions. A preliminary prospectus supplement will be filed with the SEC and made available to the public.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。